PRMT1 and neuroblastoma: To test this idea, further studies are needed to compare the potency of PRMT1 inhibitors in isolated neuroblastoma cancer stem cell fraction based on certain surface markers (i.e., CD133 and FZD6) to that in neuroblastoma cell lines from the same species.